EyePoint Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q3 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
EyePoint Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2010 to Q3 2024.
  • EyePoint Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$32.7M, a 127% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$117M, a 14.2% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$75.1M, a 24.7% increase from 2022.
  • EyePoint Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$99.6M, a 80.3% decline from 2021.
  • EyePoint Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$55.3M, a 48.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$117M -$32.7M -$18.4M -127% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$98.6M -$34.5M -$11.8M -51.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$86.8M -$33.3M -$11.8M -54.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$75.1M -$16.4M +$27.4M +62.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-08
Q3 2023 -$102M -$14.4M +$4M +21.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$106M -$22.8M -$3.55M -18.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$103M -$21.6M -$3.27M -17.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$99.6M -$43.7M -$25.7M -142% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 -$73.9M -$18.4M -$3.09M -20.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$70.9M -$19.2M -$8.24M -75% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$62.6M -$18.3M -$7.35M -67.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$55.3M -$18M -$5.31M -41.7% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-10
Q3 2021 -$50M -$15.3M -$13.4M -682% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$36.6M -$11M +$173K +1.55% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$36.8M -$10.9M +$509K +4.45% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$37.3M -$12.7M -$3.75M -41.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$33.5M -$1.96M +$12.1M +86.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$45.6M -$11.2M -$987K -9.71% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$44.7M -$11.4M +$3.21M +21.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$47.9M -$8.99M +$2.02M +18.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-16
Q3 2019 -$49.9M -$14.1M -$506K -3.73% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$49.4M -$10.2M -$383K -3.92% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$49M -$14.7M -$9.97M -213% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$39M -$11M -$5.2M -89.5% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$33.8M -$13.6M -$7.55M -126% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-16
Q2 2018 -$26.3M -$9.78M -$3.65M -59.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-16
Q1 2018 -$22.6M -$4.68M +$482K +9.34% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-16
Q4 2017 -$23.1M -$5.81M -$5.71M -6079% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-16
Q3 2017 -$17.4M -$6.01M +$1.18M +16.4% Jul 1, 2017 Sep 30, 2017 10-K 2020-03-16
Q2 2017 -$18.6M -$6.14M +$320K +4.96% Apr 1, 2017 Jun 30, 2017 10-KT 2019-03-18
Q1 2017 -$18.9M -$5.16M -$64K -1.26% Jan 1, 2017 Mar 31, 2017 10-KT 2019-03-18
Q4 2016 -$18.8M -$94K +$5.14M +98.2% Oct 1, 2016 Dec 31, 2016 10-K 2018-09-18
Q3 2016 -$24M -$7.19M -$2.2M -44.2% Jul 1, 2016 Sep 30, 2016 10-KT 2019-03-18
Q2 2016 -$21.8M -$6.46M -$1.26M -24.2% Apr 1, 2016 Jun 30, 2016 10-K 2017-09-13
Q1 2016 -$20.5M -$5.1M -$44K -0.87% Jan 1, 2016 Mar 31, 2016 10-K 2017-09-13
Q4 2015 -$20.5M -$5.24M -$1.12M -27.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-09-13
Q3 2015 -$19.4M -$4.98M -$25.8M -124% Jul 1, 2015 Sep 30, 2015 10-K 2017-09-13
Q2 2015 $6.42M -$5.2M -$1.19M -29.6% Apr 1, 2015 Jun 30, 2015 10-K 2016-09-13
Q1 2015 $7.61M -$5.05M -$2.83M -128% Jan 1, 2015 Mar 31, 2015 10-K 2016-09-13
Q4 2014 $10.4M -$4.12M -$575K -16.2% Oct 1, 2014 Dec 31, 2014 10-K 2016-09-13
Q3 2014 $11M $20.8M +$24.5M Jul 1, 2014 Sep 30, 2014 10-K 2016-09-13
Q2 2014 -$13.5M -$4.01M -$31K -0.78% Apr 1, 2014 Jun 30, 2014 10-K 2015-09-10
Q1 2014 -$13.5M -$2.22M +$593K +21.1% Jan 1, 2014 Mar 31, 2014 10-K 2015-09-10
Q4 2013 -$14.1M -$3.54M -$893K -33.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-09-10
Q3 2013 -$13.2M -$3.72M -$1.13M -43.6% Jul 1, 2013 Sep 30, 2013 10-K 2015-09-10
Q2 2013 -$12M -$3.98M -$1.67M -72.3% Apr 1, 2013 Jun 30, 2013 10-K 2014-09-11
Q1 2013 -$10.4M -$2.81M -$85K -3.12% Jan 1, 2013 Mar 31, 2013 10-K 2014-09-11
Q4 2012 -$10.3M -$2.65M +$15M +85% Oct 1, 2012 Dec 31, 2012 10-K 2014-09-11
Q3 2012 -$25.3M -$2.59M -$59K -2.33% Jul 1, 2012 Sep 30, 2012 10-K 2014-09-11
Q2 2012 -$25.2M -$2.31M -$2M -650% Apr 1, 2012 Jun 30, 2012 10-K 2013-09-27
Q1 2012 -$23.2M -$2.73M +$412K +13.1% Jan 1, 2012 Mar 31, 2012 10-K 2013-09-27
Q4 2011 -$23.6M -$17.6M -$14.5M -465% Oct 1, 2011 Dec 31, 2011 10-K 2013-09-27
Q3 2011 -$9.1M -$2.53M +$904K +26.3% Jul 1, 2011 Sep 30, 2011 10-K 2013-09-27
Q2 2011 -$10M -$308K Apr 1, 2011 Jun 30, 2011 10-K 2012-09-27
Q1 2011 -$3.14M Jan 1, 2011 Mar 31, 2011 10-K 2012-09-27
Q4 2010 -$3.12M Oct 1, 2010 Dec 31, 2010 10-K 2012-09-27
Q3 2010 -$3.44M Jul 1, 2010 Sep 30, 2010 10-K 2012-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.